Trial Profile
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Jul 2020 Results assessing whether blocking multiple points of the angiogenesis pathway by addition of sorafenib, a multi-kinase inhibitor against VEGFR2/3, Raf, c-Kit, and PDGFR, to bevacizumab would yield clinical activity in ovarian cancer published in the Gynecologic Oncology
- 08 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2013 Planned end date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.